Last reviewed · How we verify
Tc 99m filtered sulfur colloid
Tc-99m filtered sulfur colloid is a radiopharmaceutical that accumulates in the reticuloendothelial system, allowing visualization of organs and tissues via gamma imaging.
Tc-99m filtered sulfur colloid is a radiopharmaceutical that accumulates in the reticuloendothelial system, allowing visualization of organs and tissues via gamma imaging. Used for Hepatic imaging and detection of focal liver lesions, Splenic imaging, Bone marrow imaging.
At a glance
| Generic name | Tc 99m filtered sulfur colloid |
|---|---|
| Sponsor | Memorial Health University Medical Center |
| Drug class | Radiopharmaceutical diagnostic agent |
| Modality | Small molecule |
| Therapeutic area | Diagnostic Imaging |
| Phase | FDA-approved |
Mechanism of action
The sulfur colloid particles are filtered to a specific size range and labeled with technetium-99m, a gamma-emitting radioisotope. When injected intravenously, these particles are rapidly taken up by macrophages in the liver, spleen, and bone marrow, enabling scintigraphic imaging of these organs and detection of focal lesions or functional abnormalities. The filtered preparation ensures optimal particle size for hepatic uptake while minimizing bone marrow and splenic uptake.
Approved indications
- Hepatic imaging and detection of focal liver lesions
- Splenic imaging
- Bone marrow imaging
- Gastroesophageal reflux detection
- Gastrointestinal bleeding localization
Common side effects
- Allergic reaction
- Radiation exposure
Key clinical trials
- Tilmanocept vs Sulfur Colloid in Sentinel Lymph Node Biopsy (PHASE4)
- Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: